As cannabis giants stumble, vape hysteria will hit CBD too


With four Canadian cannabis giants suffering a combined $10 billion drainoff in market value since the U.S. vaping crisis that started in August, it remains to be seen how much the troubles will affect the firms’ CBD business.

Publicly traded Tilray, Canopy Growth, Aurora Cannabis and Cronos Group all have seen their stock prices tumble as the hysteria over vaping, envisioned as a major CBD sub-sector, continues to unfold in the USA. Shares in the four companies have dropped on average around 37%, with Tilray being the biggest loser at a whopping 48%.

WHOLE PLANT UTILIZATION – Firing on all CylindersLearn more about the hemp industry at the Canadian Hemp Trade Alliance’s annual conference Nov. 26 – 28, 2019; Calgary 

While CBD has yet to be directly implicated in vaping illnesses reported in the USA, all four of the Canadian companies announced initiatives and deals in CBD and vaping in recent months, projects that could be curtailed due to the rough waters. 

For reference, in U.S. states that have legalized recreational marijuana, vape commands between 10% to 25% of the total market.

To read more…

Leave a Reply

Your email address will not be published. Required fields are marked *